Evotec's Quiet Desperation: A Stock Caught Between Technical Hopes and Structural Fears

Evotec shares hover near multi-year lows with RSI in oversold territory; CEO's asset-light strategy and cost cuts fuel debate on recovery vs. continued decline.

The silence around Evotec's stock is becoming deafening. After shedding more than half its value over the past twelve months, the shares are now drifting in a zone that traders describe as eerily calm — a "dead quiet" that some interpret as the calm before a recovery and others as the stillness of a market that has simply lost interest. On Wednesday, the stock briefly flickered higher in morning trading before reversing course, settling at €3.52, down 0.73 percent on the day. That fleeting optimism evaporated just as quickly as it appeared, a pattern that has become painfully familiar for holders of the Hamburg-based drug discovery specialist.

The Technical Case for a Bounce

What keeps a flicker of hope alive is the chart. The 14-day relative strength index has dipped to 28.8, firmly in oversold territory — a level that has historically triggered at least short-term counter-moves. The secondary source puts the RSI at 29.3, but both readings tell the same story: the stock is technically stretched to the downside. It is trading barely above its multi-year low of €3.19, a level reached in July, while the gap to its 52-week high remains cavernous. The annualized volatility over the past 30 trading days underscores just how jittery the trading has become, with a yearly figure approaching 63 percent.

But technical oversold conditions alone do not make a turnaround. The stock remains well below both its 50-day and 200-day moving averages, a configuration that keeps the overarching trend firmly negative. For any sustained recovery to take hold, the price needs to defend the €3.50 level. A break below that could open the path toward the psychologically significant €3.00 mark.

The Strategy: Selling Assets to Buy Time

The fundamental picture is where the real debate lies. New CEO Christian Wojczewski has moved beyond the planning phase for his "Horizon" strategy and into execution. The plan pivots Evotec toward an "asset-light" model, shedding capital-intensive manufacturing sites to focus on its core drug discovery business. That shift has already generated significant cash: the sale of the Toulouse facility to Sandoz, completed in December 2025, brought in roughly $350 million in cash, plus potential milestone payments. The disposal of the Tubulis stake to Gilead in spring 2026 added another $100 million.

On the cost side, "Horizon" targets €75 million in annual savings by the end of 2027. If margin stabilization materializes in the second half of the year, the current enterprise value of roughly €615 million could start to look undemanding. That prospect has already sparked takeover speculation among some market participants.

The Bear Case: Cash Burn and Strategic Retreat

Yet the numbers tell a more troubling story. First-quarter 2026 revenue slumped to €156.6 million, while adjusted EBITDA swung to a loss of €21.9 million. Critics argue that selling the J.POD facility in Toulouse amounted to a strategic retreat — Evotec gave up a technological edge in biologics manufacturing to plug a short-term hole in its balance sheet. Restructuring provisions of €75 million are further weighing on earnings.

The cash position stood at €444.8 million at the end of the first quarter, but with the core business still burning through money, the question is whether the asset sales have bought enough time for the restructuring to bear fruit. The half-year report due in August will be the next major test. Investors will be watching two metrics above all: the trajectory of cash reserves and the first measurable evidence that "Horizon" is delivering on its cost targets.

Waiting for the Fed

Wednesday's subdued trading in Evotec is not happening in a vacuum. The broader market is holding its breath ahead of the Federal Reserve's interest rate decision. The DAX managed a modest gain on Tuesday, but the Nasdaq 100 has now fallen for five consecutive sessions on valuation concerns in the technology sector. In an environment where even large-cap growth stocks are under pressure, speculative capital for beaten-down small caps like Evotec is scarce. Investors are waiting for clearer monetary policy signals before committing to high-risk, high-reward positions.

For now, Evotec remains trapped between two narratives: the technical hope of a bounce from oversold levels and the fundamental skepticism of a market that has seen the stock lose a third of its value in a matter of weeks. Without fresh operational catalysts, the shares are likely to continue oscillating between recovery fantasies and the cold reality of a company still in the middle of a painful transformation.